^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    3d
    PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov)
    P3, N=153, Recruiting, AiCuris Anti-infective Cures AG | Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Jan 2025 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Zyclara (imiquimod)
    7d
    Saliva PCR in Pregnant Women with COVID-19 (clinicaltrials.gov)
    P=N/A, N=37, Completed, National Cheng-Kung University Hospital
    New trial
    10d
    CanTreatCOVID: Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings (clinicaltrials.gov)
    P3, N=10000, Recruiting, Unity Health Toronto | Trial completion date: Jan 2025 --> Mar 2026 | Trial primary completion date: Jan 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    17d
    MOVe-NOW: A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (clinicaltrials.gov)
    P3, N=3082, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    A Study of RBD1016 in CHB Participants (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Suzhou Ribo Life Science Co. Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    18d
    Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (clinicaltrials.gov)
    P3, N=748, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    19d
    Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (clinicaltrials.gov)
    P3, N=328, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    19d
    Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (clinicaltrials.gov)
    P1, N=36, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    19d
    PROLIFIC: ImPROving Quality of LIFe in the Long COVID Patient (clinicaltrials.gov)
    P2, N=219, Completed, Karolinska Institutet | Active, not recruiting --> Completed
    Trial completion • HEOR
    |
    ritonavir
    26d
    Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Arbutus Biopharma Corporation | Not yet recruiting --> Recruiting | N=35 --> 50
    Enrollment open • Enrollment change
    1m
    A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Dose Escalation (with optional food effect) Study of Orally Administered TRX-100 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of TRX-100 in Healthy Volunteers (ACTRN12624000891527)
    P1, N=40, Recruiting, Trawsfynydd Therapeutics AU Pty Ltd (on behalf of Traws Pharma, Inc.) | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    1m
    An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers (clinicaltrials.gov)
    P1, N=14, Completed, TrippBio, Inc. | Not yet recruiting --> Completed | Trial primary completion date: Jul 2024 --> Sep 2024
    Trial completion • Trial primary completion date
    1m
    A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (clinicaltrials.gov)
    P1, N=14, Completed, TrippBio, Inc. | Not yet recruiting --> Completed | Trial primary completion date: Jul 2024 --> Sep 2024
    Trial completion • Trial primary completion date
    1m
    Study of Obeldesivir as Postexposure Prophylaxis for Marburg Virus Disease (clinicaltrials.gov)
    P2, N=400, Not yet recruiting, Gilead Sciences
    New P2 trial
    1m
    The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data (ChiCTR2400089338)
    P=N/A, N=200, Not yet recruiting, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and
    New trial
    2ms
    Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P1 trial
    2ms
    A Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of Multiple Doses of ALG-000184. (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Aligos Therapeutics
    New P1 trial
    |
    itraconazole
    2ms
    A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Peking University Third Hospital
    New trial
    2ms
    Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Sichuan Provincial People's Hospital
    New trial • Real-world evidence • Real-world
    2ms
    MOVe-NOW: A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (clinicaltrials.gov)
    P3, N=3082, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    2ms
    A Study of RBD1016 in CHB Participants (clinicaltrials.gov)
    P2, N=48, Recruiting, Suzhou Ribo Life Science Co. Ltd. | N=104 --> 48
    Enrollment change
    2ms
    A Study of JNJ-64281802 for the Prevention of Dengue Infection (clinicaltrials.gov)
    P2, N=1256, Terminated, Janssen Research & Development, LLC | N=1850 --> 1256 | Trial completion date: May 2025 --> Jun 2024 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Jun 2024; The study was stopped due to portfolio reprioritization. This decision is not based on any safety concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    2ms
    A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants (clinicaltrials.gov)
    P2, N=0, Withdrawn, Janssen Research & Development, LLC | N=54 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    2ms
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, GemVax & Kael | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    LucaVax (tertomotide)
    2ms
    GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov)
    P2, N=78, Completed, GemVax & Kael | Recruiting --> Completed | Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    LucaVax (tertomotide)
    2ms
    Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2, N=240, Recruiting, Gilead Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (clinicaltrials.gov)
    P1, N=40, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P1 trial
    2ms
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=56, Recruiting, GemVax & Kael | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LucaVax (tertomotide)
    2ms
    A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov)
    P2, N=60, Recruiting, Vigonvita Life Sciences | Trial primary completion date: Sep 2024 --> Jan 2025
    Trial primary completion date
    3ms
    A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2/3, N=16, Terminated, Pfizer | Active, not recruiting --> Terminated; Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study.
    Trial termination
    3ms
    A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV (clinicaltrials.gov)
    P1, N=10, Terminated, Pfizer | N=108 --> 10 | Trial completion date: Apr 2025 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Sep 2024; Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    3ms
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, GemVax & Kael
    New P1 trial
    |
    LucaVax (tertomotide)
    3ms
    A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) (clinicaltrials.gov)
    P1, N=64, Completed, Merck Sharp & Dohme LLC
    New P1 trial
    3ms
    PROLIFIC: imPROving Quality of LIFe In the Long COVID Patient (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Karolinska Institutet | Recruiting --> Active, not recruiting | N=400 --> 180 | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Jan 2024 --> Nov 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • HEOR
    |
    ritonavir
    3ms
    COVID: Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, National Taiwan University Hospital
    New trial
    3ms
    A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Antiva Biosciences | N=29 --> 110 | Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A expression
    3ms
    A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients (clinicaltrials.gov)
    P2, N=135, Completed, Oneness Biotech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    3ms
    Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma. (PubMed, Biomaterials)
    As expected, application of ERV improved the efficacy of anti-PD1. Overall, our results approved that ERV enhances the efficacy of anti-PD1 immunotherapy in melanoma by promoting the polarization of M1 macrophages, which provided novel therapeutic strategy for improving the effectiveness of melanoma anti-PD1 immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CCL5 (Chemokine (C-C motif) ligand 5) • MAPK8 (Mitogen-activated protein kinase 8)
    3ms
    A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia (ChiCTR2400087137)
    P4, N=16, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New P4 trial
    3ms
    A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2/3, N=6, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=2715 --> 6 | Trial completion date: Mar 2026 --> Sep 2024 | Trial primary completion date: Mar 2026 --> Sep 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    4ms
    Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Gilead Sciences
    New P2 trial
    4ms
    Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (clinicaltrials.gov)
    P3, N=748, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P3 trial